In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-like carbapenemase-producing acinetobacter baumannii strains belonging to sequence type 357

Applied and Environmental Microbiology

Volumn 82, Issue 14, 2016, Pages 4200-4208

  Jeon, Jongsoo ^a   Ryu, Choong Min ^c,d   Lee, Jun Young ^b   Park, Jong Hwan ^b   Yong, Dongeun ^a   Lee, Kyungwon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chonnam National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d University of Science and Technology (UST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGES; BIOINFORMATICS; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; INTENSIVE CARE UNITS; MAMMALS; PH EFFECTS; SHELLFISH; TRANSMISSION ELECTRON MICROSCOPY;

BACTERIAL CHALLENGE; BACTERIOLYTIC ACTIVITY; BIOINFORMATICS ANALYSIS; CLINICAL ISOLATES; GENOME SEQUENCING; MULTIDRUG RESISTANTS; THERAPEUTIC AGENTS; THERAPEUTIC EFFECTS;

GENES;

ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; BACTERIUM; BIOINFORMATICS; BIOTECHNOLOGY; DISEASE CONTROL; DISEASE PREVALENCE; DNA; GENETIC ANALYSIS; GENOMICS; PUBLIC HEALTH;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); MUS;

BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMAL; BACTERIOPHAGE; BIOLOGY; CLASSIFICATION; DISEASE MODEL; DNA SEQUENCE; ENZYMOLOGY; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HOST RANGE; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MOUSE; MULTILOCUS SEQUENCE TYPING; PATHOLOGY; PH; PHAGE THERAPY; PHYSIOLOGY; PNEUMONIA, BACTERIAL; PROCEDURES; SECRETION (PROCESS); SURVIVAL ANALYSIS; TIME FACTOR; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT OUTCOME; ULTRASTRUCTURE; VIRION; VIROLOGY; VIRUS ATTACHMENT; VIRUS GENOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; BACTERIAL PROTEINS; BACTERIOPHAGES; BETA-LACTAMASES; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; GENOME, VIRAL; GENOTYPE; HOST SPECIFICITY; HYDROGEN-ION CONCENTRATION; LUNG; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MULTILOCUS SEQUENCE TYPING; PHAGE THERAPY; PNEUMONIA, BACTERIAL; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VIRION; VIRUS ATTACHMENT;

EID: 84977575523     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.00526-16     Document Type: Article

References (47)

1. Ackermann HW. 1996. Frequency of morphological phage descriptions in 1995. Arch Virol 141:209-218. http://dx.doi.org/10.1007/BF01718394.
2. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage 1:66-85. http://dx.doi.org/10.4161/bact.1 .2.15845.
3. Mahony J, McAuliffe O, Ross RP, van Sinderen D. 2011. Bacteriophages as biocontrol agents of food pathogens. Curr Opin Biotechnol 22:157-163. http://dx.doi.org/10.1016/j.copbio.2010.10.008.
4. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2:489-497. http://dx .doi.org/10.1038/nrd1111.
5. Sulakvelidze A, Alavidze Z, Morris JG, Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659. http://dx.doi.org/10.1128 /AAC.45.3.649-659.2001.
6. Wittebole X, De Roock S, Opal SM. 2014. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5:226-235. http://dx.doi.org/10.4161/viru .25991.
7. Nilsson AS. 2014. Phage therapy-constraints and possibilities. Ups J Med Sci 119:192-198. http://dx.doi.org/10.3109/03009734.2014.902878.
8. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591-595. http://dx.doi.org/10.1016/j.tibtech.2010.08.001.
9. Cohen ML. 1992. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050 -1055. http://dx.doi.org/10 .1126/science.257.5073.1050.
10. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122-S129. http://dx.doi.org/10 .1038/nm1145.
11. Norrby SR, Nord CE, Finch R, European Society of Clinical Microbiology and Infectious Diseases. 2005. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 5:115-119. http://dx.doi.org/10.1016/S1473-3099(05)70086-4.
12. Tenover FC. 2001. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis 33(Suppl 3):S108-S115. http://dx.doi.org/10.1086/321834.
13. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. 2013. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 41:11-19. http://dx.doi.org/10.1016/j.ijantimicag.2012 .09.008.
14. Munoz-Price LS, Weinstein RA. 2008. Acinetobacter infection. N Engl J Med 358:1271-1281. http://dx.doi.org/10.1056/NEJMra070741.
15. Higgins PG, Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 65:233-238. http://dx.doi.org/10.1093/jac/dkp428.
16. Nordmann P, Poirel L. 2002. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect 8:321-331. http://dx.doi.org/10 .1046/j.1469-0691.2002.00401.x.
17. Durante-Mangoni E, Zarrilli R. 2011. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol 6:407-422. http://dx.doi.org /10.2217/fmb.11.23.
18. Vila J, Pachon J. 2012. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother 13:2319-2336. http://dx.doi.org/10.1517/14656566.2012.729820.
19. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484. http://dx.doi.org/10.1128 /AAC.01464-06.
20. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27:351-353. http://dx.doi.org/10.1016/j.ijantimicag.2006.01.004.
21. Lee K, Kim CK, Yong D, Jeong SH, Yum JH, Seo YH, Docquier JD, Chong Y. 2010. Improved performance of the modified Hodge test with MacConkey agar for screening carbapenemase-producing Gram-negative bacilli. J Microbiol Methods 83:149-152. http://dx.doi.org/10.1016/j .mimet.2010.08.010.
22. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. 2009. Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol 501:69-76. http://dx.doi.org/10.1007/978-1-60327 -164-6_7.
23. Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ. 2010. Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol 161:308-314. http://dx.doi.org/10.1016/j.resmic .2010.03.007.
24. Wilcox SA, Toder R, Foster JW. 1996. Rapid isolation of recombinant lambda phage DNA for use in fluorescence in situ hybridization. Chromosome Res 4:397-398. http://dx.doi.org/10.1007/BF02257276.
25. Besemer J, Lomsadze A, Borodovsky M. 2001. GeneMarkS: a selftraining method for prediction of gene starts in microbial genomes. Implications for finding sequence motifs in regulatory regions. Nucleic Acids Res 29:2607-2618.
26. Darling AC, Mau B, Blattner FR, Perna NT. 2004. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res 14:1394-1403. http://dx.doi.org/10.1101/gr.2289704.
27. Sullivan MJ, Petty NK, Beatson SA. 2011. Easyfig: a genome comparison visualizer. Bioinformatics 27:1009 -1010. http://dx.doi.org/10 .1093/bioinformatics/btr039.
28. Lowe TM, Eddy SR. 1997. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. Nucleic Acids Res 25:955-964. http://dx.doi.org/10.1093/nar/25.5.0955.
29. Manepalli S, Gandhi JA, Ekhar VV, Asplund MB, Coelho C, Martinez LR. 2013. Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis. J Med Microbiol 62:1747-1754. http://dx.doi.org/10.1099/jmm.0 .060004-0.
30. Henry M, Lavigne R, Debarbieux L. 2013. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 57:5961-5968. http://dx.doi.org/10.1128/AAC .01596-13.
31. Mann NH. 2008. The potential of phages to prevent MRSA infections. Res Microbiol 159:400-405. http://dx.doi.org/10.1016/j.resmic.2008.04.003.
32. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org /10.2217/fmb.13.47.
33. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:1607-1615. http://dx.doi.org/10 .1093/jac/dks084.
34. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60:1163-1167. http://dx.doi.org/10.1093/jac/dkm305.
35. Peng F, Mi Z, Huang Y, Yuan X, Niu W, Wang Y, Hua Y, Fan H, Bai C, Tong Y. 2014. Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolates. BMC Microbiol 14:181. http://dx.doi.org/10.1186/1471-2180-14-181.
36. Thawal ND, Yele AB, Sahu PK, Chopade BA. 2012. Effect of a novel podophage AB7-IBB2 on Acinetobacter baumannii biofilm. Curr Microbiol 65:66-72. http://dx.doi.org/10.1007/s00284-012-0127-2.
37. Merabishvili M, Vandenheuvel D, Kropinski AM, Mast J, De Vos D, Verbeken G, Noben JP, Lavigne R, Vaneechoutte M, Pirnay JP. 2014. Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii. PLoS One 9:e104853. http://dx.doi.org/10.1371 /journal.pone.0104853.
38. Li P, Chen B, Song Z, Song Y, Yang Y, Ma P, Wang H, Ying J, Ren P, Yang L, Gao G, Jin S, Bao Q, Yang H. 2012. Bioinformatic analysis of the Acinetobacter baumannii phage AB1 genome. Gene 507:125-134. http://dx.doi.org/10.1016/j.gene.2012.07.029.
39. Jeon J, Kim JW, Yong D, Lee K, Chong Y. 2012. Complete genome sequence of the podoviral bacteriophage YMC/09/02/B1251 ABA BP, which causes the lysis of an OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolate from a septic patient. J Virol 86:12437-12438. http://dx.doi.org/10.1128/JVI.02132-12.
40. Lee CN, Tseng TT, Lin JW, Fu YC, Weng SF, Tseng YH. 2011. Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumannii and phage phiKO2. Appl Environ Microbiol 77:6755-6762. http://dx.doi.org/10.1128/AEM.05116-11.
41. Popova AV, Zhilenkov EL, Myakinina VP, Krasilnikova VM, Volozhantsev NV. 2012. Isolation and characterization of wide host range lytic bacteriophage AP22 infecting Acinetobacter baumannii. FEMS Microbiol Lett 332:40-46. http://dx.doi.org/10.1111/j.1574-6968.2012.02573.x.
42. Soothill JS. 1992. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 37:258-261. http://dx.doi.org/10.1099 /00222615-37-4-258.
43. Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P. 2009. In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene. Antimicrob Agents Chemother 53:2657-2659. http://dx.doi.org/10.1128/AAC.01663-08.
44. Sung JY, Koo SH, Cho HH, Kwon KC. 2013. Nosocomial infection by sequence type 357 multidrug-resistant Acinetobacter baumannii isolates in a neonatal intensive care unit in Daejeon, Korea. Ann Lab Med 33:279-282. http://dx.doi.org/10.3343/alm.2013.33.4.279.
45. Oshiro S, Tada T, Kameoka Y, Suzuki K, Ohmagari N, Miyoshi-Akiyama T, Kirikae T. 2015. Development and evaluation of immunochromatography to detect Gram-negative bacteria producing ArmA 16S rRNA methylase responsible for aminoglycoside resistance. J Microbiol Methods 118:159-163. http://dx.doi.org/10.1016/j.mimet.2015.09.005.
46. Jin J, Li ZJ, Wang SW, Wang SM, Huang DH, Li YH, Ma YY, Wang J, Liu F, Chen XD, Li GX, Wang XT, Wang ZQ, Zhao GQ. 2012. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol 12:156. http://dx.doi.org/10 .1186/1471-2180-12-156.
47. Yang H, Liang L, Lin S, Jia S. 2010. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol 10:131. http://dx.doi.org/10.1186/1471-2180-10-131.